Retirement Systems of Alabama Raises Stock Holdings in Eli Lilly and Company $LLY

Retirement Systems of Alabama lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 169,593 shares of the company’s stock after acquiring an additional 800 shares during the period. Retirement Systems of Alabama’s holdings in Eli Lilly and Company were worth $129,399,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Brighton Jones LLC boosted its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. OneAscent Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 32.0% during the 2nd quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after purchasing an additional 87 shares during the period. BankPlus Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 2.5% during the second quarter. BankPlus Wealth Management LLC now owns 1,006 shares of the company’s stock worth $784,000 after purchasing an additional 25 shares during the last quarter. Finally, Patron Partners LLC grew its position in shares of Eli Lilly and Company by 6.7% in the second quarter. Patron Partners LLC now owns 3,968 shares of the company’s stock valued at $3,093,000 after purchasing an additional 250 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on LLY shares. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Wednesday, January 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a report on Monday, November 10th. Finally, Leerink Partners set a $1,234.00 price target on shares of Eli Lilly and Company in a research note on Monday, January 5th. Four analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $1,174.61.

Eli Lilly and Company Trading Down 2.1%

NYSE LLY opened at $1,065.05 on Friday. The firm has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.11, a PEG ratio of 0.80 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company’s 50 day moving average price is $1,057.19 and its 200 day moving average price is $880.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bernstein raised conviction on LLY, projecting a $1,300 target on expectations that Lilly’s weight‑loss pill will be a blockbuster — this supports upside and keeps buy-side interest alive. Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share
• Positive Sentiment: Pipeline progress: Lilly reported advancement of early‑stage LY4064809, signaling continued R&D momentum that can de‑risk future growth beyond GLP‑1s. Eli Lilly Advances Early-Stage LY4064809 Study
• Positive Sentiment: Device/delivery gains: Lilly completed a device study for remternetug delivery options — positive for convenience/uptake and formulary discussions. Eli Lilly Advances Remternetug Delivery Options With Completed Device Study
• Positive Sentiment: Late‑stage obesity program: Lilly launched a Phase 3b dosing study for retatrutide, which, if successful, strengthens near‑term growth visibility in obesity. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Oncology tailwind: Analyst pieces highlight Verzenio and new oncology launches as incremental revenue drivers that broaden the story beyond GLP‑1s. Here’s How Eli Lilly’s Oncology Drugs Are Poised Ahead of Q4 Earnings
• Neutral Sentiment: Industry outlook: Executives at JPMorgan H.C. said the obesity market will expand into more pills, combos and easier access — a market‑wide constructive view but it raises competitive and margin questions. What obesity drugmakers see next in the market
• Neutral Sentiment: Corporate moves: Lilly named Pranav Shroff director of marketing — a routine leadership update with limited near‑term financial impact. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Critical take: Opinion pieces urge investors to consider alternatives to Lilly, arguing the stock’s high valuation is driven largely by GLP‑1 enthusiasm — this kind of narrative can trigger profit‑taking. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
• Negative Sentiment: Competition risk: Sun Pharma won a Wegovy generic nod in India, setting up tougher pricing/market dynamics in a key growth market for obesity drugs. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market
• Negative Sentiment: Regulatory/legal headline: Coverage of a lawsuit over insulin pricing keeps regulatory and reputational risk in focus for investors. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.